查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1976602

性行为感染感染检测市场：依检测类型、产品类型、技术、疾病类型、检体类型、最终用户和通路划分－2026-2032年全球预测

STD Testing Market by Test Type, Product, Technology, Disease Type, Sample Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，性行为感染感染检测市场价值将达到 105.8 亿美元，到 2026 年将成长至 112.2 亿美元，到 2032 年将达到 160.3 亿美元，复合年增长率为 6.12%。

主要市场统计数据
基准年 2025 105.8亿美元
预计年份：2026年 112.2亿美元
预测年份 2032 160.3亿美元
复合年增长率 (%) 6.12%

对当前性行为感染检测现状的权威观点，这种现状受到创新、获取压力和不断发展的医疗保健服务模式的影响。

由于技术进步、政策重点转变和医疗服务模式演变等因素的共同作用，性行为感染（STI）检测领域正经历着快速且持续的变革。公共卫生计画、临床检查室和照护现场机构都在积极回应日益增长的对更快、更准确、更便捷诊断的需求，同时还要应对诸如社会污名、报销不均和法规环境波动等持续存在的障碍。这些矛盾正在改变从集中式参考检查室到分散式照护现场机构等各种场所的检测方法的开发、检验和实施方式。

分子诊断、非侵入性采样、数位整合以及经销模式的创新如何改变性行为感染感染检测和临床决策的提供方式？

该领域正经历多重转折点，这些转折点正在改变临床路径、供应链和患者体验。首先，分子诊断已从专业检查室转移到更贴近患者的场所，这得益于简化的工作流程和强大的检体到结果平台。这使得核酸扩增技术能够提供更早、更可靠的检测。同时，等温扩增技术的进步和横向流动化验化学的改进缩小了快速检测和检查室检测之间的性能差距，从而为临床环境中的即时决策提供了更多选择。

评估 2025 年关税变化对整个诊断设备、试剂盒和检测生态系统中最终用户韧性的累积供应链和采购影响。

2025年推出的最新贸易政策变化对支撑性行为感染感染诊断生态系统的整个采购、製造和分销管道产生了累积影响。影响进口设备、试剂盒和组件的关税调整给供应链带来了压力，促使製造商和经销商重新评估筹资策略和库存管理实践。因此，诊断检查室、医院和参考检测中心的采购团队不得不权衡确保持续获得​​检测服务的需求与营运现实（例如前置作业时间波动和与供应商的谈判）之间的关係。

综合細項分析揭示了测试类型、最终用户需求、产品形式、技术选择、通路、目标疾病和检体类型如何决定策略重点。

详细的細項分析揭示了性行为感染感染检测领域中产品开发、分销和临床应用在多个维度上的差异。就检测类型而言，培养检测在抗菌药物敏感性试验和确诊流程中仍然至关重要，而琼脂培养和细胞培养则继续支持一些专门的检查室功能。核酸增幅检查涵盖了基于PCR的平台和等温扩增方法。 PCR在灵敏度高的检测中仍然发挥核心作用，而等温扩增方法则提供了一种更简单快捷的方式，适用于分散式环境。快速检测包括横向流动化验和照护现场平台，这些平台优先考虑速度和易用性，而酵素免疫分析法和侧向层析免疫检测支持筛检和流行病学监测。

区域流行病学、法规环境、生产能力和分销策略如何影响世界各地检测的部署状况和获取途径的差异？

区域趋势导致流行病学、法规结构、生产能力和医疗服务模式等方面有显着差异，进而影响检测计画的实施。在美洲，积极的私部门参与和完善的检测网络与公共卫生筛检计画并存。在数位化结果交付和广泛分发管道的支持下，就地检验和居家筛检在该地区日益普及。这些趋势有利于那些将强大的检测能力与以用户为中心的设计以及与电子健康记录和病例报告系统深度整合相结合的解决方案。

竞争格局洞察突显了技术差异化、伙伴关係、监管策略和服务导向模式如何影响市场定位和渗透率。

性行为感染感染诊断领域的竞争趋势是由技术差异化、策略伙伴关係以及超越核心检测能力的基于服务的交付模式共同塑造的。主要企业正投资于提升分析灵敏度和特异性的能力，同时透过简化工作流程和整合数位化报告来优化使用者体验。这种组合为那些能够支援在中心实验室和以患者为中心的环境中部署、展现实际效用和完善品质系统的企业提供了机会。

经营团队可采取的策略重点，以加强供应韧性、加速照护现场部署、整合数位化工作流程，并与监管机构和公共卫生合作伙伴合作。

产业领导者应采取能够增强韧性、加速产品普及并最大限度地提升不同医疗环境下临床应用效果的策略。优先考虑供应链多元化并确保关键零件的多个来源，可降低贸易中断和关税风险。投资本地生产和区域组装将缩短前置作业时间并有助于符合监管要求。同时，加速利用等温扩增和改进的侧向流动化学技术开发就地检验和快速检测方法，将使即时检测结果能够惠及当地社区和分散式医疗机构，从而实现及时治疗和通知合作伙伴。

本研究结果的得出方法透明性（有关主要访谈、次要证据整合、細項分析和品质保证通讯协定的详细资讯）。

本报告的研究采用了综合性的混合方法，以确保分析的严谨性、情境有效性和可重复性。主要研究包括对临床实验室经理、照护现场专案管理人员、采购负责人和监管专家进行结构化访谈，以了解营运限制、推广应用驱动因素和采购考量。除访谈外，与诊断研发公司和分销合作伙伴的讨论也为了解产品开发蓝图和分销策略提供了重要资讯。

一份简洁、全面的分析报告，重点阐述了创新、营运韧性和跨部门合作如何塑造性行为感染检测实施和普及之路。

总而言之，目前性行为感染感染检测的现状反映了技术进步与实施复杂性之间的平衡。儘管核酸扩增技术、照护现场平台和非侵入性采样技术的进步正在扩展诊断能力，但供应链韧性、监管差异和分销物流等实际操作因素仍然限制实施路径。相关人员，将更有能力将创新转化为更佳的临床疗效。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：性行为感染感染检测市场

  • 培养试验
    • 琼脂培养法
    • 细胞培养
  • 核酸增幅检查
    • 等温扩增法
    • 基于PCR的
  • 快速检测
    • 横向流动化验
    • 照护现场平台
  • 血清学检测
    • 酵素免疫分析法
    • 横向流动化验

第九章：性行为感染感染检测市场：依产品划分

  • 装置
  • 成套工具
  • 软体和服务

第十章：性行为感染感染检测市场：依技术划分

  • 酵素免疫分析法
  • 等温扩增
  • 横向流动化验
  • 基于PCR的

第十一章：性行为感染感染检测市场：依疾病类型划分

  • 披衣菌感染
  • 淋病
  • 疱疹
  • HIV
  • 梅毒

第十二章 依检体类型分類的性行为感染感染检测市场

  • 血
  • 唾液
  • 棉花棒
  • 尿

第十三章：性行为感染感染侦测市场：依最终用户划分

  • 诊断检查室
  • 医院和诊所
  • 就地检验设施
  • 参考测试机构

第十四章：性行为感染传染感染检测市场：依通路划分

  • 离线
  • 在线的

第十五章：性行为感染感染检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：性行为感染感染检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章性行为感染感染检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国性行为感染感染检测市场

第十九章：中国性行为感染感染检测市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Access Medical Laboratories Inc.
  • ARCpoint Labs
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • OraSure Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
Product Code: MRR-69324464D0F2

The STD Testing Market was valued at USD 10.58 billion in 2025 and is projected to grow to USD 11.22 billion in 2026, with a CAGR of 6.12%, reaching USD 16.03 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.58 billion
Estimated Year [2026] USD 11.22 billion
Forecast Year [2032] USD 16.03 billion
CAGR (%) 6.12%

An authoritative orientation to the current sexually transmitted disease testing environment shaped by innovation, access pressures, and evolving care delivery models

The landscape of sexually transmitted disease testing is undergoing rapid and sustained transformation as technological advances converge with shifting policy priorities and evolving patterns of care delivery. Public health programs, clinical laboratories, and point-of-care providers are responding to rising demand for faster, more accurate, and accessible diagnostics while confronting persistent barriers such as stigma, inconsistent reimbursement, and variable regulatory environments. These tensions are reshaping how tests are developed, validated, and delivered across multiple settings, from centralized reference laboratories to decentralized point-of-care locations.

Diagnostics developers and health systems are prioritizing innovations that reduce time to result, expand non-invasive sampling, and enable multiplexed detection of pathogens to streamline clinical decision-making. At the same time, digital health integration and software-enabled workflows are improving data capture, reporting, and patient linkage to care. As a result, stakeholders across the value chain are increasingly focused on interoperability, quality assurance, and the practicalities of scaling novel testing modalities in diverse clinical and community contexts.

To navigate this environment, leaders must interpret technical advances in the context of operational realities and regulatory constraints while preserving equitable access. The following sections unpack the transformative shifts, tariff-related impacts, segmentation insights, and region-specific considerations that collectively define the current moment for STD testing.

How innovations in molecular methods, non-invasive sampling, digital integration, and distribution models are reshaping STD testing delivery and clinical decision-making

The field has experienced several transformative shifts that are altering clinical pathways, supply chains, and patient experiences. First, molecular diagnostics have migrated from specialized laboratories to near-patient settings through simplified workflows and robust sample-to-answer platforms, enabling nucleic acid amplification technologies to drive earlier and more reliable detection. Concurrently, advances in isothermal amplification techniques and improvements in lateral flow assay chemistry have narrowed performance gaps between rapid tests and laboratory-based assays, expanding options for immediate decision-making at the point of care.

Second, the expansion of non-invasive sample types such as saliva and self-collected swabs is lowering barriers to testing and enabling broader screening initiatives outside traditional clinical settings. This shift is complemented by software and services that support remote result delivery, patient follow-up, and electronic case reporting, creating more integrated care pathways. Third, distribution and procurement channels have diversified as manufacturers and distributors adopt omnichannel strategies, including direct sales, distributor networks, and online platforms that reach community-based organizations and home-testing consumers.

Finally, regulatory modernization and public health priorities have encouraged adaptive study designs and accelerated pathways for clinically-validated assays, while emerging attention to antimicrobial resistance underscores the need for diagnostics that inform treatment selection. Together, these shifts demand coordinated responses from developers, laboratories, and health authorities to ensure diagnostic performance, equitable access, and sustainability of testing programs.

Evaluating the cumulative supply chain and procurement consequences of 2025 tariff shifts on diagnostics instruments, kits, and end-user resilience across the testing ecosystem

Recent trade policy changes introduced in 2025 have produced cumulative effects across procurement, manufacturing, and distribution channels that serve the sexually transmitted disease diagnostics ecosystem. Tariff adjustments impacting imported instruments, kits, and component parts have pressured supply chains, prompting manufacturers and distributors to reassess sourcing strategies and inventory management practices. As a consequence, procurement teams in diagnostic laboratories, hospitals, and reference centers have had to balance the imperative for uninterrupted testing access with the operational realities of lead-time variability and supplier negotiation.

In response, some stakeholders have accelerated localization efforts for critical components and explored alternative suppliers across regions to reduce exposure to trade-related volatility. These adjustments have implications for product portfolios, as developers consider how instrument designs and consumable formats influence cross-border logistics and regulatory compliance. For point-of-care testing sites and online channels that rely on rapid replenishment, the tariff-driven dynamics have highlighted the importance of resilient distribution agreements and transparent pricing arrangements with manufacturers and distributors.

Moreover, tariffs have catalyzed renewed emphasis on software and services as value differentiators, with diagnostics providers investing in service packages that mitigate supply disruptions for end users. Regulatory pathways and reimbursement conversations must adapt alongside procurement strategies to preserve patient access to timely testing, and stakeholders are increasingly collaborating on contractual safeguards and contingency plans that protect routine screening and outbreak response capabilities.

Integrated segmentation analysis explains how test type, end-user needs, product form factors, technology selection, distribution channels, disease targets, and sample types drive strategic priorities

A granular view of segmentation reveals how product development, distribution, and clinical adoption vary across multiple dimensions of the STD testing landscape. When considering test type, culture tests remain relevant for antimicrobial susceptibility and confirmatory workflows, with agar-based culture and cell culture continuing to support specialized laboratory functions. Nucleic acid amplification tests encompass both PCR-based platforms and isothermal amplification methods; PCR maintains a central role for high-sensitivity detection while isothermal approaches enable simplified, rapid formats suited to decentralized settings. Rapid tests include lateral flow assays and point-of-care platforms that prioritize speed and ease of use, whereas serology testing through enzyme immunoassays and lateral flow immunoassays supports screening and epidemiological surveillance.

End users exhibit distinct operational requirements: diagnostic laboratories and reference laboratories prioritize throughput, quality control, and integration into laboratory information systems, hospitals and clinics focus on workflow efficiency and clinician-facing interpretability, and point-of-care testing sites emphasize ease of use, rapid turnaround, and linkage to care. Product types span instruments, where durability and compatibility with diverse consumables matter, kits that demand consistent supply chain assurance and shelf stability, and software and services that enhance data management, result reporting, and remote patient engagement. Technologies such as enzyme immunoassay, isothermal amplification, lateral flow assay, and PCR each present trade-offs between sensitivity, specificity, cost, and operational complexity.

Distribution channels-direct sales, distributors, and online channels-shape market reach and user support models, influencing how quickly new assays penetrate clinical practice. Disease-specific dynamics vary by pathogen: chlamydia and gonorrhea testing protocols often emphasize nucleic acid amplification for high diagnostic accuracy, herpes relies on a combination of direct detection and serology depending on clinical context, HIV testing integrates both rapid screening and confirmatory molecular assays, and syphilis diagnostics require sensitive serology with reflex testing strategies. Sample types influence user experience and adoption, with blood and serum samples remaining standard for serology, urine and swab specimens favored for many nucleic acid assays, and saliva increasingly used for user-friendly screening initiatives. Collectively, these segmentation layers inform product design, regulatory strategy, and commercialization pathways for developers and service providers.

How regional epidemiology, regulatory ecosystems, manufacturing capability, and distribution strategies shape differential adoption and access across global regions

Regional dynamics introduce critical contextual differences in epidemiology, regulatory frameworks, manufacturing capacity, and care delivery models that shape testing program implementation. In the Americas, substantial private sector participation and established laboratory networks coexist with active public health screening programs; the region shows strong uptake of point-of-care testing and home-based screening, supported by digital result delivery and broad distribution channels. These dynamics favor solutions that combine robust laboratory performance with user-focused design and strong connectivity to electronic health records and case reporting systems.

Europe, Middle East & Africa presents a heterogenous landscape characterized by stringent regulatory pathways in some markets, resource constraints in others, and variable disease prevalence across countries. Here, diagnostics developers must balance cost-effectiveness with rigorous validation and support capacity building for laboratory infrastructure. Partnerships with regional distributors and public health agencies are pivotal to expanding access and ensuring quality assurance, particularly for reference laboratories and programs focused on surveillance and outbreak response.

Asia-Pacific encompasses major manufacturing hubs and rapidly expanding diagnostic adoption, with a strong emphasis on scalable production, mobile health integration, and online distribution models. High-volume manufacturing capacity supports cost-competitive kit production, while rising investments in point-of-care platforms and telehealth services drive demand for non-invasive sampling and rapid result delivery. Across all regions, harmonizing regulatory submissions, strengthening local validation studies, and tailoring distribution strategies are essential to align product deployment with public health goals and clinical workflows.

Competitive landscape insights highlighting how technological differentiation, partnerships, regulatory strategy, and service-oriented models influence market positioning and adoption

Competitive dynamics in the STD diagnostics space are shaped by a mix of technological differentiation, strategic partnerships, and service-based offerings that extend beyond core assay performance. Leading developers are investing in features that improve analytical sensitivity and specificity while optimizing user experience through simplified workflows and integrated digital reporting. This combination supports adoption in both centralized laboratories and near-patient environments, creating opportunities for companies that can demonstrate real-world utility and robust quality systems.

Strategic alliances between instrument manufacturers, kit suppliers, and distribution partners are increasingly common as companies seek to accelerate market access and reduce time-to-adoption in clinical settings. Additionally, firms that pair diagnostics with software and services-such as connectivity solutions, training, and after-sales support-gain competitive advantage by addressing implementation barriers faced by hospitals, clinics, and point-of-care providers. Intellectual property around novel amplification chemistries and multiplexing approaches remains a differentiator, as does the ability to secure regulatory clearances across multiple jurisdictions.

Market actors are also exploring differentiated commercial models, including subscription-based access to instruments and consumables, bundled service agreements that include quality control and training, and targeted programs for public health customers that emphasize affordability and scale. These approaches reflect a broader pivot toward solutions that integrate product performance with practical deployment support to drive sustainable uptake.

Actionable strategic priorities for executives to strengthen supply resilience, accelerate point-of-care uptake, integrate digital workflows, and collaborate with regulators and public health partners

Industry leaders should pursue strategies that enhance resilience, accelerate access, and maximize clinical impact across diverse care settings. Prioritizing supply chain diversification and dual-source procurement for critical components will reduce exposure to trade disruptions and tariffs while investments in localized manufacturing or regional assembly can shorten lead times and support regulatory alignment. Concurrently, accelerating development of point-of-care and rapid testing modalities that leverage isothermal amplification and improved lateral flow chemistries will expand reach into community and decentralized settings where immediate results facilitate timely treatment and partner notification.

Leaders should also strengthen digital integration by embedding connectivity, automated reporting, and decision-support capabilities into test platforms and service offerings. This integration improves surveillance, simplifies case management, and enhances the value proposition for hospitals and public health partners. Commercially, adopting omnichannel distribution strategies-combining direct sales for large institutional customers, distributor relationships for regional penetration, and online channels for broader consumer access-will optimize market reach and responsiveness.

Finally, organizations should engage proactively with regulators and public health stakeholders to streamline validation pathways, participate in collaborative studies that demonstrate clinical utility across diverse populations, and design pricing and access programs that reduce barriers for high-need communities. By coupling technological innovation with pragmatic deployment strategies and stakeholder engagement, firms can drive sustainable improvements in testing coverage and clinical outcomes.

Methodological transparency detailing primary interviews, secondary evidence synthesis, segmentation analysis, and quality assurance protocols used to derive research findings

The research underpinning this report employed a comprehensive mixed-methods approach designed to ensure analytical rigor, contextual relevance, and reproducibility. Primary research included structured interviews with clinical laboratory directors, point-of-care program managers, procurement officers, and regulatory specialists to capture operational constraints, adoption drivers, and procurement considerations. These interviews were supplemented by consultations with diagnostic developers and distribution partners to understand product development roadmaps and channel strategies.

Secondary research encompassed systematic review of peer-reviewed literature, regulatory guidance documents, white papers, and publicly available technical specifications to validate performance characteristics and technology attributes. Data triangulation methods were applied to reconcile insights from primary interviews with documented evidence, ensuring consistency across qualitative and quantitative indicators. Segmentation analysis was performed across test type, end-user category, product typology, technology, distribution channel, disease target, and sample type to derive actionable insights for developers and purchasers.

Quality assurance protocols included cross-validation of interview findings, iterative review cycles with subject-matter experts, and transparent documentation of assumptions and limitations. Ethical standards for interview consent and data handling were observed throughout. While the methodology emphasizes current, evidence-based analysis, the report avoids speculative forecasting and instead focuses on empirical drivers and pragmatic implications for stakeholders.

A concise synthesis emphasizing how innovation, operational resilience, and cross-sector collaboration determine the trajectory of STD testing implementation and access

In synthesis, the current STD testing landscape reflects a balance between technological progress and implementation complexity. Advances in nucleic acid amplification, point-of-care platforms, and non-invasive sampling are expanding diagnostic capabilities, yet operational realities such as supply chain resilience, regulatory variability, and distribution logistics continue to temper adoption pathways. Stakeholders who align product design with end-user workflows, invest in digital connectivity, and proactively manage procurement risks will be better positioned to translate innovation into improved clinical outcomes.

Regional differences underscore the importance of tailored strategies, whether that means leveraging manufacturing strengths and online channels in Asia-Pacific, navigating regulatory and public health partnerships in Europe, Middle East & Africa, or integrating point-of-care and home-testing models across the Americas. Disease-specific needs and sample type considerations further refine deployment choices, informing where multiplex assays, serology platforms, or culture-based confirmation remain most appropriate. Ultimately, cross-sector collaboration among manufacturers, laboratories, clinicians, payers, and public health authorities is essential to scale testing programs that are both effective and equitable.

Moving forward, disciplined attention to quality, interoperability, and stakeholder engagement will determine which innovations achieve sustainable integration into clinical practice. By focusing on pragmatic implementation and resilient commercial strategies, the sector can expand access to high-quality testing and strengthen the continuum of care for individuals and communities affected by sexually transmitted infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. STD Testing Market, by Test Type

  • 8.1. Culture Tests
    • 8.1.1. Agar Based Culture
    • 8.1.2. Cell Culture
  • 8.2. Nucleic Acid Amplification Tests
    • 8.2.1. Isothermal Amplification
    • 8.2.2. PCR Based
  • 8.3. Rapid Tests
    • 8.3.1. Lateral Flow Assays
    • 8.3.2. Point Of Care Platforms
  • 8.4. Serology Tests
    • 8.4.1. Enzyme Immunoassay
    • 8.4.2. Lateral Flow Assays

9. STD Testing Market, by Product

  • 9.1. Instruments
  • 9.2. Kits
  • 9.3. Software And Services

10. STD Testing Market, by Technology

  • 10.1. Enzyme Immunoassay
  • 10.2. Isothermal Amplification
  • 10.3. Lateral Flow Assay
  • 10.4. PCR Based

11. STD Testing Market, by Disease Type

  • 11.1. Chlamydia
  • 11.2. Gonorrhea
  • 11.3. Herpes
  • 11.4. HIV
  • 11.5. Syphilis

12. STD Testing Market, by Sample Type

  • 12.1. Blood
  • 12.2. Saliva
  • 12.3. Swab
  • 12.4. Urine

13. STD Testing Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals And Clinics
  • 13.3. Point Of Care Testing Sites
  • 13.4. Reference Laboratories

14. STD Testing Market, by Distribution Channel

  • 14.1. Offline
  • 14.2. Online

15. STD Testing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. STD Testing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. STD Testing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States STD Testing Market

19. China STD Testing Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. Access Medical Laboratories Inc.
  • 20.7. ARCpoint Labs
  • 20.8. Becton Dickinson and Company
  • 20.9. Bio-Rad Laboratories, Inc.
  • 20.10. Danaher Corporation
  • 20.11. F. Hoffmann-La Roche AG
  • 20.12. Hologic, Inc.
  • 20.13. Laboratory Corporation of America Holdings
  • 20.14. OraSure Technologies, Inc.
  • 20.15. Quest Diagnostics Incorporated
  • 20.16. Quidel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STD TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL STD TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STD TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL STD TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL STD TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL STD TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL STD TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL STD TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL STD TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL STD TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS STD TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL STD TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GCC STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 232. GCC STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GCC STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. G7 STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 266. G7 STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 268. G7 STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. G7 STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. NATO STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. NATO STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. NATO STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 279. NATO STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 280. NATO STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. NATO STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. NATO STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. NATO STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL STD TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA STD TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)